Insider buying last 90 days
No open-market insider purchases were filed for PTGX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Protagonist Therapeutics moved this week on Q3 2026 results and an FDA approval. The company reported EPS of $3.07 on revenue of $274.41 million, swinging to a $220.0 million net income from a $39.3 million loss a year earlier, with earnings and revenue surpassing estimates. The FDA approved MIMRYLO (rusfertide) for erythrocytosis in adults with polycythemia vera, triggering $275 million in payments to the company. Wall Street Zen upgraded the stock to "Strong-Buy," aligning with a broader "Buy" consensus and an average price target cited at $166.67.
PTGX closed at $135.90, up 2.9%, sitting between its 50-day average of $141.35 and 200-day average of $118.24. The stock has gained 31.3% over six months and 70.3% over the past year, though it is down 5.4% over one month and 8.4% over three months. The GekkoIndex reads 62, placing the stock in the Accumulation zone. Price sits 13.1% below the Gekko Fair Value of $156.34.
Over the next 20 trading days, the next earnings date falls on 24 February 2027, 101 days away, outside a typical holding window. Insider, Congress and unusual options activity show no data in their respective windows, though one billionaire holder is noted. Thirteen analyst firms carry buy ratings, with a consensus target of $178.57 and consensus upside of 31.4%. Seasonality from this point has averaged a 5% gain over 20 trading days across 5 years, rising in 2 of them, with typical 20-day moves near 10.1%.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Protagonist Therapeutics scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
Averages disagree
Close $130.95 sits between the 50-day ($140.30) and 200-day ($119.29) averages, or the averages disagree.
See the chart63.2, Accumulation
Reading 63.2 is in the Accumulation zone.
See the GekkoIndex16.7% below
Price is 16.7% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 101 days
Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.
See earnings+4.0% on average
From this point in the calendar, the next 20 trading days averaged +4% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Protagonist Therapeutics closed at $130.95 on Nov 13, 2026, +54.3% over the past year, inside a 52-week range of $77.00 to $160.81.
Use the left and right arrow keys to read daily values.
Put PTGX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Protagonist Therapeutics develops therapies built around peptide molecules, with work concentrated on blood disorders and on conditions driven by inflammation or immune activity. It is best recognized for rusfertide, also called PTG-300, an injectable compound that mimics hepcidin and is being tested in Phase II studies for polycythemia vera, hereditary hemochromatosis, and related blood conditions. Alongside this, the company is developing PN-943, an oral peptide designed to block alpha-4-beta-7 integrin for inflammatory bowel disease, and PN-235, an oral compound aimed at the interleukin-23 receptor for both IBD and other conditions outside that category.
The company advances its pipeline in part through a licensing and collaborative arrangement with Janssen Biotech, Inc., pairing its own drug discovery work with an outside partner as programs move through development.
Protagonist Therapeutics was founded in 2006 and is headquartered in Newark, California. Its shares trade on the NASDAQ under the ticker PTGX.
Protagonist Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.2, in the Accumulation zone, down 0.8 points over five sessions.
Down 0.8 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 7 | Too few readings yet | |||
| Accumulation (current zone) | 159 | +1.8% | +5.7% | ||
| Neutral | 492 | +1.5% | +6.3% | ||
| Distribution | 40 | −0.9% | +0.6% | ||
| Selling | 4 | Too few readings yet | |||
Average PTGX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Protagonist Therapeutics trades 16.7% below Gekko Fair Value of $157.12, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Protagonist Therapeutics shares are worth, recalculated every trading day.
$157.12
Gekko Fair Value, Nov 14, 2026
16.7% Undervalued
At the end of Aug 2026 the price was 7.3% below the estimate.
No open-market insider purchases were filed for Protagonist Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for PTGX in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in PTGX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Protagonist Therapeutics has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds PTGX.
Protagonist Therapeutics reports on Feb 24, 2027, after the close (101 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 24, 2027
Expected after the close, 101 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $2.29 est $2.23 | $213.5M est $198.7M | +7.6% |
| May 5, 2026 | $0.05 est −$0.65 | $56.37M est $11.70M | +4.5% |
| Feb 25, 2026 | −$0.69 est −$0.53 | $7.44M est $8.74M | +1.1% |
| Nov 6, 2025 | −$0.62 est −$0.59 | $4.71M est $14.92M | +2.1% |
| Aug 6, 2025 | −$0.55 est −$0.53 | $5.55M est $8.43M | −5.5% |
| May 6, 2025 | −$0.19 est −$0.50 | $28.32M est $6.56M | −2.7% |
| Feb 21, 2025 | $1.98 est $0.06 | $170.6M est $81.01M | −6.5% |
| Nov 7, 2024 | −$0.54 est −$0.59 | $4.68M est $38.81M | −2.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Protagonist Therapeutics is $182.36, +39.3% from the last close, from 13 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 13 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 10 | UBS | $184 | +40.5% |
| Nov 9 | Wedbush | $173 | +32.1% |
| Nov 9 | BMO Capital | $190 | +45.1% |
| Nov 9 | J.P. Morgan | $151 | +15.3% |
| Nov 6 | H.C. Wainwright | $221 | +68.8% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Protagonist Therapeutics averaged +4.0% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.2% | 2 of 5 |
| Next 10 trading days | −0.3% | 3 of 5 |
| Next 15 trading days | +3.7% | 2 of 5 |
| Next 20 trading days | +4.0% | 3 of 5 |
| Next 30 trading days | +11.1% | 3 of 5 |
For scale, PTGX’s typical 20-trading-day move in either direction is about 10.1%.
Protagonist Therapeutics’s market cap is $8.55B, with a P/E ratio of 28.1 and revenue of $551.7M over the last twelve months.
Coverage of Protagonist Therapeutics this week reads positive: 3 positive, 0 neutral and 0 negative headlines.
Protagonist Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Protagonist Therapeutics’s market cap is $8.55B at the Nov 13, 2026 close of $130.95, with 65.27M shares outstanding. The shares trade on a P/E ratio of 28.1.
The consensus analyst 12-month price target for Protagonist Therapeutics is $182.36, +39.3% from the last close. Of the 13 firms that rated the stock in the last 90 days, 13 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Protagonist Therapeutics is undervalued: the Nov 13, 2026 close of $130.95 is 16.7% below Gekko Fair Value of $157.12. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Protagonist Therapeutics is expected to report on Feb 24, 2027, after the market closes (101 days away). Analysts expect earnings of −$0.15 per share on revenue of $45.42M. Protagonist Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 4.1% on average across the report.
Protagonist Therapeutics’s 52-week high is $160.81 and its 52-week low is $77.00; it closed at $130.95 on Nov 13, 2026, +54.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.